{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:55:01Z","timestamp":1794858901716,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is characterized by a profoundly immunosuppressive tumor microenvironment (TME) that constrains the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Here, we show that surgical resection in both male mice and human GBM ex vivo induces a rapid and sustained remodeling of the TME, marked by upregulation of TREM2 in myeloid cells followed by emergence of T cell exhaustion-like phenotypes. In male mice, targeting TREM2 reshapes the perioperative TME and potentiates tumor antigen-specific CAR-T cell responses, improving intratumoral persistence, proliferation, and effector differentiation, and resulting in enhanced survival. In parallel, we identify the timing of CAR-T cell administration as a critical determinant of therapeutic outcome, with neoadjuvant outperforming adjuvant treatment by preserving CAR-T cell effector function in mice. These findings establish perioperative myeloid cell remodeling and treatment timing as key determinants of CAR-T cell efficacy in GBM.<\/jats:p>","DOI":"10.1038\/s41467-026-76206-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:48Z","timestamp":1785521088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1258-7825","authenticated-orcid":false,"given":"Martin","family":"Pedard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Castillo Cantero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Marinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzel","family":"Davanture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Widmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0247-2007","authenticated-orcid":false,"given":"Doron","family":"Merkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Egervari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-2757","authenticated-orcid":false,"given":"Philippe","family":"Bijlenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahan","family":"Momjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2060-4691","authenticated-orcid":false,"given":"Mikael J.","family":"Pittet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-4237","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0151-3222","authenticated-orcid":false,"given":"Denis","family":"Migliorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"76206_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jama.2023.2234","volume":"329","author":"R Marcus","year":"2023","unstructured":"Marcus, R. What Is Glioblastoma? JAMA 329, 1232 (2023).","journal-title":"JAMA"},{"key":"76206_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Zhou, F., Ali, H., Lathia, J. D. & Chen, P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell. Mol. Immunol. 21, 1354\u20131375 (2024).","journal-title":"Cell. Mol. Immunol."},{"key":"76206_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665742","volume":"16","author":"N Nicolaou","year":"2025","unstructured":"Nicolaou, N., Andreou, M. S., Neophytou, C. M. & Papageorgis, P. Emerging insights into the immunosuppressive tumor microenvironment and its implications for glioblastoma immunotherapy. Front. Immunol. 16, 1665742 (2025).","journal-title":"Front. Immunol."},{"key":"76206_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu, U. & June, C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 43, 506\u2013515 (2025).","journal-title":"Nat. Biotechnol."},{"key":"76206_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665\u2013679 (2025).","journal-title":"Cancer Cell"},{"key":"76206_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00753-0","volume":"8","author":"S Park","year":"2024","unstructured":"Park, S., Maus, M. V. & Choi, B. D. CAR-T cell therapy for the treatment of adult high-grade gliomas. npj Precis. Oncol. 8, 279 (2024).","journal-title":"npj Precis. Oncol."},{"key":"76206_CR7","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.7150\/thno.114257","volume":"15","author":"M Ijaz","year":"2025","unstructured":"Ijaz, M. et al. Overcoming barriers in glioblastoma: the potential of CAR T cell immunotherapy. Theranostics 15, 7090\u20137126 (2025).","journal-title":"Theranostics"},{"key":"76206_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"76206_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111971","volume":"42","author":"N Ochocka","year":"2023","unstructured":"Ochocka, N. et al. Specialized functions and sexual dimorphism explain the functional diversity of the myeloid populations during glioma progression. Cell Rep. 42, 111971 (2023).","journal-title":"Cell Rep."},{"key":"76206_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.trecan.2022.12.008","volume":"9","author":"MB Watowich","year":"2023","unstructured":"Watowich, M. B., Gilbert, M. R. & Larion, M. T cell exhaustion in malignant gliomas. Trends Cancer 9, 270\u2013292 (2023).","journal-title":"Trends Cancer"},{"key":"76206_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet, M. J., Michielin, O. & Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402\u2013421 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76206_CR12","doi-asserted-by":"publisher","unstructured":"Akay, F. & Saleh, M. Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives. Front. Immunol. 16 https:\/\/doi.org\/10.3389\/fimmu.2025.1472710 (2025).","DOI":"10.3389\/fimmu.2025.1472710"},{"key":"76206_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/neuonc\/noab302","volume":"24","author":"AM Knudsen","year":"2022","unstructured":"Knudsen, A. M. et al. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors. Neuro Oncol. 24, 1074\u20131087 (2022).","journal-title":"Neuro Oncol."},{"key":"76206_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13046-024-03231-4","volume":"43","author":"C Bastiancich","year":"2024","unstructured":"Bastiancich, C. et al. Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment. J. Exp. Clin. Cancer Res. 43, 311 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"76206_CR15","doi-asserted-by":"crossref","unstructured":"Khalsa, J. K. & Cheng, N. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. 11, 3912 (2020).","DOI":"10.1038\/s41467-020-17704-5"},{"key":"76206_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63692-9","volume":"16","author":"EG Graham-Gurysh","year":"2025","unstructured":"Graham-Gurysh, E. G. et al. Post-resection delivery of a TLR7\/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice. Nat. Commun. 16, 8603 (2025).","journal-title":"Nat. Commun."},{"key":"76206_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01533-2","author":"Y Kaiser","year":"2025","unstructured":"Kaiser, Y. et al. Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01533-2 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"76206_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1368732","volume":"14","author":"Y Lv","year":"2024","unstructured":"Lv, Y. et al. Prospects and challenges of CAR-T cell therapy combined with ICIs. Front. Oncol. 14, 1368732 (2024).","journal-title":"Front. Oncol."},{"key":"76206_CR19","doi-asserted-by":"crossref","unstructured":"Shen, S. H. et al. IL-12 secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma. J. ImmunoTher. Cancer 14, e012532 (2026).","DOI":"10.1136\/jitc-2025-012532"},{"key":"76206_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005187","volume":"10","author":"G Tessa","year":"2022","unstructured":"Tessa, G. et al. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. J. Immunother. Cancer 10, e005187 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"76206_CR21","doi-asserted-by":"publisher","unstructured":"Hatae, R. et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight 9 https:\/\/doi.org\/10.1172\/jci.insight.177141 (2024).","DOI":"10.1172\/jci.insight.177141"},{"key":"76206_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2024","unstructured":"Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240\u2013261 (2024).","journal-title":"Nat. Cancer"},{"key":"76206_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200891","volume":"32","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1. Mol. Ther. Oncol. 32, 200891 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"76206_CR24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","volume":"25","author":"TF Cloughesy","year":"2019","unstructured":"Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477\u2013486 (2019).","journal-title":"Nat. Med."},{"key":"76206_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26940-2","volume":"12","author":"AH Lee","year":"2021","unstructured":"Lee, A. H. et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat. Commun. 12, 6938 (2021).","journal-title":"Nat. Commun."},{"key":"76206_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 470\u2013476 (2019).","journal-title":"Nat. Med."},{"key":"76206_CR27","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","volume":"31","author":"GV Long","year":"2025","unstructured":"Long, G. V. et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat. Med. 31, 1557\u20131566 (2025).","journal-title":"Nat. Med."},{"key":"76206_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/neuonc\/noz185","volume":"22","author":"J de Groot","year":"2020","unstructured":"de Groot, J. et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 22, 539\u2013549 (2020).","journal-title":"Neuro Oncol."},{"key":"76206_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s43018-025-00990-7","volume":"6","author":"G Awada","year":"2025","unstructured":"Awada, G. et al. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types. Nat. Cancer 6, 967\u2013987 (2025).","journal-title":"Nat. Cancer"},{"key":"76206_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/neuonc\/noab182","volume":"24","author":"P Chuntova","year":"2021","unstructured":"Chuntova, P. et al. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. Neuro Oncol. 24, 259\u2013272 (2021).","journal-title":"Neuro Oncol."},{"key":"76206_CR31","doi-asserted-by":"publisher","first-page":"e1501137","DOI":"10.1080\/2162402X.2018.1501137","volume":"7","author":"V Genoud","year":"2018","unstructured":"Genoud, V. et al. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology 7, e1501137 (2018).","journal-title":"Oncoimmunology"},{"key":"76206_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/neuonc\/noad214","volume":"26","author":"J Zheng","year":"2024","unstructured":"Zheng, J. et al. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro Oncol. 26, 811\u2013825 (2024).","journal-title":"Neuro Oncol."},{"key":"76206_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade3559","volume":"9","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma. Sci. Adv. 9, eade3559 (2023).","journal-title":"Sci. Adv."},{"key":"76206_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.001","author":"J Zhong","year":"2024","unstructured":"Zhong, J. et al. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. Cancer cell https:\/\/doi.org\/10.1016\/j.ccell.2024.05.001 (2024).","journal-title":"Cancer cell"},{"key":"76206_CR35","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn, D. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432\u20131447.e1417 (2023).","journal-title":"Cell"},{"key":"76206_CR36","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464.e1420 (2023).","journal-title":"Cell"},{"key":"76206_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"76206_CR38","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","volume":"43","author":"D Stahl","year":"2025","unstructured":"Stahl, D. et al. CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell 43, 1476\u20131494.e1410 (2025).","journal-title":"Cancer Cell"},{"key":"76206_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01830-x","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer. Mol. Cancer 22, 131 (2023).","journal-title":"Mol. Cancer"},{"key":"76206_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan, Z., Wang, C., Wu, J., Wang, J. & Ma, T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol. Biomed. 6, 27 (2025).","journal-title":"Mol. Biomed."},{"key":"76206_CR41","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka, K. et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175\u20134186 (2018).","journal-title":"Clin. Cancer Res."},{"key":"76206_CR42","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00262-022-03358-3","volume":"72","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Interaction of glioma-associated microglia\/macrophages and anti-PD1 immunotherapy. Cancer Immunol. Immunother. 72, 1685\u20131698 (2023).","journal-title":"Cancer Immunol. Immunother."},{"key":"76206_CR43","doi-asserted-by":"publisher","first-page":"v34","DOI":"10.1093\/neuonc\/noae144.103","volume":"26","author":"A Ballest\u00edn","year":"2024","unstructured":"Ballest\u00edn, A. et al. A Surgical resection-induced ischemia drived glioblastoma cell plasticity and tumor microenvironment adaptation. Neuro Oncol. 26, v34\u2013v34 (2024).","journal-title":"Neuro Oncol."},{"key":"76206_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ccell.2024.08.012","volume":"42","author":"SS Watson","year":"2024","unstructured":"Watson, S. S. et al. Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. Cancer Cell 42, 1507\u20131527.e1511 (2024).","journal-title":"Cancer Cell"},{"key":"76206_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70252","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. An adoptive cell therapy with TREM2-overexpressing macrophages mitigates the transition from acute kidney injury to chronic kidney disease. Clin. Transl. Med. 15, e70252 (2025).","journal-title":"Clin. Transl. Med."},{"key":"76206_CR46","doi-asserted-by":"crossref","unstructured":"Yalcin, F., Dzaye, O. & Xia, S. in Tumor Microenvironment: Extracellular Matrix Components \u2013 Part B (ed Alexander Birbrair) 149\u2013172 (Springer International Publishing, 2020).","DOI":"10.1007\/978-3-030-48457-6_9"},{"key":"76206_CR47","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.cell.2020.05.003","volume":"181","author":"A Deczkowska","year":"2020","unstructured":"Deczkowska, A., Weiner, A. & Amit, I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell 181, 1207\u20131217 (2020).","journal-title":"Cell"},{"key":"76206_CR48","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","volume":"17","author":"RL Bowman","year":"2016","unstructured":"Bowman, R. L. et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 17, 2445\u20132459 (2016).","journal-title":"Cell Rep."},{"key":"76206_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28372-y","volume":"13","author":"N Abdelfattah","year":"2022","unstructured":"Abdelfattah, N. et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat. Commun. 13, 767 (2022).","journal-title":"Nat. Commun."},{"key":"76206_CR50","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41593-022-01089-3","volume":"25","author":"R Sankowski","year":"2022","unstructured":"Sankowski, R. et al. Author Correction: mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat. Neurosci. 25, 975 (2022).","journal-title":"Nat. Neurosci."},{"key":"76206_CR51","doi-asserted-by":"publisher","unstructured":"Binnewies, M. et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37 https:\/\/doi.org\/10.1016\/j.celrep.2021.109844 (2021).","DOI":"10.1016\/j.celrep.2021.109844"},{"key":"76206_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct. Target. Ther. 10, 268 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76206_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2025.11.009","volume":"44","author":"G Yagel","year":"2026","unstructured":"Yagel, G. et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell 44, 519\u2013533.e510 (2026).","journal-title":"Cancer Cell"},{"key":"76206_CR54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2025.12.021","volume":"44","author":"J Mateus-Tique","year":"2026","unstructured":"Mateus-Tique, J. et al. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. Cancer Cell 44, 534\u2013550.e511 (2026).","journal-title":"Cancer Cell"},{"key":"76206_CR55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum, D. et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell 187, 149\u2013165.e123 (2024).","journal-title":"Cell"},{"key":"76206_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41420-024-01809-7","volume":"10","author":"C Ramos","year":"2024","unstructured":"Ramos, C. & Oehler, R. Clearance of apoptotic cells by neutrophils in inflammation and cancer. Cell Death Discov. 10, 26 (2024).","journal-title":"Cell Death Discov."},{"key":"76206_CR57","doi-asserted-by":"publisher","unstructured":"Liu, T. et al. CAR-T triggers TAM reeducation and adaptive anti-tumor response via <em>TREM2<\/em> deficiency or CD40 agonist. Cell Rep. Med. 7 https:\/\/doi.org\/10.1016\/j.xcrm.2025.102539 (2026).","DOI":"10.1016\/j.xcrm.2025.102539"},{"key":"76206_CR58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania, J. et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 58, 232\u2013246.e236 (2025).","journal-title":"Immunity"},{"key":"76206_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.devcel.2024.10.010","volume":"60","author":"Z Tang","year":"2025","unstructured":"Tang, Z. et al. A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression. Dev. Cell 60, 379\u2013395.e378 (2025).","journal-title":"Dev. Cell"},{"key":"76206_CR60","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637, 708\u2013715 (2025).","journal-title":"Nature"},{"key":"76206_CR61","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","volume":"30","author":"R Ciccone","year":"2024","unstructured":"Ciccone, R. et al. GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma. Clin. Cancer Res. 30, 2545\u20132557 (2024).","journal-title":"Clin. Cancer Res."},{"key":"76206_CR62","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41591-024-03449-x","volume":"31","author":"C Quintarelli","year":"2025","unstructured":"Quintarelli, C. et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Nat. Med. 31, 849\u2013860 (2025).","journal-title":"Nat. Med."},{"key":"76206_CR63","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli, F. et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat. Med. 31, 3689\u20133699 (2025).","journal-title":"Nat. Med."},{"key":"76206_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1249929","volume":"14","author":"P Machy","year":"2023","unstructured":"Machy, P., Mortier, E. & Birkl\u00e9, S. Biology of GD2 ganglioside: implications for cancer immunotherapy. Front. Pharm. 14, 1249929 (2023).","journal-title":"Front. Pharm."},{"key":"76206_CR65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1158\/1078-0432.CCR-08-2151","volume":"15","author":"TF Liu","year":"2009","unstructured":"Liu, T. F., Cai, J., Gibo, D. M. & Debinski, W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin. Cancer Res. 15, 160\u2013168 (2009).","journal-title":"Clin. Cancer Res."},{"key":"76206_CR66","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","volume":"8","author":"CE Brown","year":"2013","unstructured":"Brown, C. E. et al. Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis. PloS ONE 8, e77769 (2013).","journal-title":"PloS ONE"},{"key":"76206_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.radonc.2007.04.025","volume":"83","author":"SA Weppler","year":"2007","unstructured":"Weppler, S. A. et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother. Oncol. 83, 333\u2013339 (2007).","journal-title":"Radiother. Oncol."},{"key":"76206_CR68","doi-asserted-by":"publisher","first-page":"67196","DOI":"10.18632\/oncotarget.11950","volume":"7","author":"X Zhou","year":"2016","unstructured":"Zhou, X. et al. TGF-\u03b21 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155\/miR-143 axis. Oncotarget 7, 67196\u201367211 (2016).","journal-title":"Oncotarget"},{"key":"76206_CR69","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.7150\/thno.105947","volume":"15","author":"Z Ma","year":"2025","unstructured":"Ma, Z. et al. Histone lactylation-driven B7-H3 expression promotes tumor immune evasion. Theranostics 15, 2338\u20132359 (2025).","journal-title":"Theranostics"},{"key":"76206_CR70","doi-asserted-by":"publisher","unstructured":"Bailey, C. M. et al. Targeting HIF-1\u03b1 abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J. Clin. Investig. 132 https:\/\/doi.org\/10.1172\/jci150846 (2022).","DOI":"10.1172\/jci150846"},{"key":"76206_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng, D. H. et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cell exhaustion. Nat. Commun. 11, 4520 (2020).","journal-title":"Nat. Commun."},{"key":"76206_CR72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","volume":"18","author":"Q Hu","year":"2025","unstructured":"Hu, Q., Zhu, Y., Mei, J., Liu, Y. & Zhou, G. Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy. J. Hematol. Oncol. 18, 65 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"76206_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1330-2","volume":"15","author":"J Qian","year":"2018","unstructured":"Qian, J. et al. The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy. J. Neuroinflamm. 15, 290 (2018).","journal-title":"J. Neuroinflamm."},{"key":"76206_CR74","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/neuonc\/noad257","volume":"26","author":"MM Peshoff","year":"2024","unstructured":"Peshoff, M. M. et al. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro Oncol. 26, 826\u2013839 (2024).","journal-title":"Neuro Oncol."},{"key":"76206_CR75","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a Trem2-dependent manner. Cell 178, 686\u2013698.e614 (2019).","journal-title":"Cell"},{"key":"76206_CR76","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1757360","volume":"9","author":"S Murty","year":"2020","unstructured":"Murty, S. et al. Intravital imaging reveals synergistic effect of CAR T-cells and radiation therapy in a preclinical immunocompetent glioblastoma model. Oncoimmunology 9, 1757360 (2020).","journal-title":"Oncoimmunology"},{"key":"76206_CR77","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nmeth.4579","volume":"15","author":"ML Squadrito","year":"2018","unstructured":"Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods 15, 183\u2013186 (2018).","journal-title":"Nat. Methods"},{"key":"76206_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2025.103706","volume":"6","author":"A Scafidi","year":"2025","unstructured":"Scafidi, A., Lind-Holm Mogensen, F. & Michelucci, A. Protocol for the generation and assessment of functional macrophages from mouse bone marrow cells. STAR Protoc. 6, 103706 (2025).","journal-title":"STAR Protoc."},{"key":"76206_CR79","doi-asserted-by":"publisher","first-page":"83701","DOI":"10.18632\/oncotarget.13295","volume":"7","author":"VN Yadav","year":"2016","unstructured":"Yadav, V. N. et al. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: a genetic knockdown study. Oncotarget 7, 83701\u201383719 (2016).","journal-title":"Oncotarget"},{"key":"76206_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34175-y","volume":"13","author":"WH Tomaszewski","year":"2022","unstructured":"Tomaszewski, W. H. et al. Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma. Nat. Commun. 13, 6483 (2022).","journal-title":"Nat. Commun."},{"key":"76206_CR81","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/2159-8290.CD-24-1056","volume":"15","author":"A Ugolini","year":"2025","unstructured":"Ugolini, A. et al. Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation. Cancer Discov. 15, 1270\u20131296 (2025).","journal-title":"Cancer Discov."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76206-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76206-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:05:29Z","timestamp":1789085129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76206-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76206"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76206-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.M. is an inventor of patents related to CAR-T cell therapy, filed by the University of Pennsylvania, the Universita della Svizzera Italiana, and the University of Geneva. D.M. is the scientific co-founder, and serves as a consultant for Cellula Therapeutics SA, as well as a consultant for Limula and MPC Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9727"}}